{"Clinical Trial ID": "NCT00723398", "Intervention": ["INTERVENTION 1:", "Group 1: Monitoring", "Control, no intervention", "INTERVENTION 2:", "Group 2: Raloxifene 60 mg", "Raloxifene 60 mg orally daily"], "Eligibility": ["Incorporation criteria:", "A postmenopausal condition defined as a history of at least 12 months without spontaneous menstrual bleeding or documented hysterectomy and bilateral salpingo oophorectomy", "- Breast density greater than 25%", "No hormone replacement therapy for at least six months prior to entry into this study", "Non-smokers.", "- Exclusion criteria:", "\u2022 History of stroke, pulmonary embolism or deep venous thrombosis", "\u2022 History of atherosclerosis heart disease", "Presence of any known hypercoagulable state, whether congenital (e.g. S protein deficiency) or acquired (e.g. corticosteroid therapy)", "Diabetes mellitus rate", "Uncontrolled hypertension (BP 140/90)", "Presence of a psychiatric disorder that would interfere with protocol compliance."], "Results": ["Performance measures:", "Change in absolute breast density", "No other mammograms will be obtained or used for this study. The absolute volume of breast density is based on breast thickness and X-ray attenuation at each pixel of the image.", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Group 1: Control", "Description of the arm/group: Control, no intervention", "Total number of participants analysed: 53", "Average (standard deviation)", "Unit of measurement: square cm Absolute density at base: 53 participants", "- 65.53 (59.43)", "\u2022 Absolute density at 1 year: 48 participants", "- 59.29 (40.72)", "\u2022 Absolute density at 2 years: 46 participants", "- 54.34 (20.11)", "Results 2:", "Title of arm/group: Group 2: Raloxifene 60 mg", "Description of the arm/group: Raloxifene 60 mg orally daily", "Total number of participants analysed: 53", "Average (standard deviation)", "Unit of measurement: square cm Absolute density at base: 53 participants", "64.39 (39.95)", "\u2022 Absolute density at 1 year: 41 participants", "60.48 (38.89)", "\u2022 Absolute density at 2 years: 38 participants", "- 60.57 (35.10)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/53 (0.00 per cent)", "Endometrial cancer [1]0/53 (0.00 %)", "Adverse Events 2:", "Total: 1/53 (1.89%)", "Endometrial cancer [1]1/53 (1.89%)"]}